TERN Terns Pharmaceuticals, Inc.

CIK 0001831363 26 ready 8-Ks latest May 5, 2026, 7:59 PM ET RSS · JSON

Ready 8-Ks 26

Latest filing May 5, 2026, 7:59 PM ET

Top materiality 1.00

Event mix other_material ×10 · earnings ×6 · leadership ×5

Sentiment 9 pos · 1 neg · 16 neu

Latest earnings reported 2025-Q3

Executive change recent →

Recent 8-K filings for TERN

Highest-materiality recent filing

Terns Pharmaceuticals acquired by Merck for $53/share; shares to be delisted

May 5, 2026, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 3.01 item 5.01 item 5.03 item 3.03 item 5.02 item 8.01 item 9.01

Offer expired May 4, 2026 with 100,091,794 shares (86.36%) validly tendered; minimum condition met.
On May 5, Purchaser accepted tendered shares and promptly merged Terns into a wholly owned Merck subsidiary.

Read filing →

May 5, 2026, 7:59 PM ET M&A materiality 1.00 neutral item 2.01 item 3.01 item 5.01 item 5.03 item 3.03 item 5.02 item 8.01 item 9.01

Terns Pharmaceuticals acquired by Merck for $53/share; shares to be delisted

Offer expired May 4, 2026 with 100,091,794 shares (86.36%) validly tendered; minimum condition met.
April 27, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

FDA grants Breakthrough Therapy Designation to TERN-701; Merck acquisition mentioned in press release

FDA Breakthrough Therapy Designation for TERN-701 in Ph+ CML-CP patients without T315I mutation, previously treated with 2+ TKIs.
March 25, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01 item 7.01 item 9.01

Merck to acquire Terns for $53.00/share ($6.7B equity value); adds CML candidate TERN-701

Merck subsidiary will pay $53.00 per share in cash, representing ~$6.7B equity value; ~$5.7B net of acquired cash.
January 9, 2026, 6:59 PM ET other material materiality 0.70 positive item 2.02 item 9.01

Terns announces $1.0B cash runway; TERN-701 pivotal trial planned late 2026/early 2027

Year-end 2025 unaudited cash ~$1.0B, expected to fund operations into 2031 including potential TERN-701 launch.
December 11, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

Terns Pharmaceuticals prices upsized $650M public offering of 16.25M shares at $40/share

Public offering of 16.25M shares at $40/share upsized; underwriters' option for 2.44M shares exercised in full.
December 8, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Terns reports 64% MMR rate in Phase 1 CARDINAL trial of TERN-701 in CML; selects 320/500 mg RP2D

Overall MMR rate of 64% (18/28) achieved by 24 weeks; cumulative MMR rate 74% (28/38).
November 10, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Terns reports Q3 net loss $24.6M; TERN-701 CML data 75% MMR at 24 weeks; halts TERN-601 GLP-1 obesity program

TERN-701 Phase 1 CARDINAL trial: overall MMR rate 75% by 24 weeks; 69% in patients with lack of efficacy to prior TKI.
November 3, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

TERN-701 Phase 1 CARDINAL trial shows 75% cumulative MMR rate by 24 weeks in refractory CML; abstract at ASH

75% (24/32) overall cumulative MMR rate by 24 weeks; 64% (14/22) achieved MMR, 100% (10/10) maintained MMR, no MMR loss.
October 22, 2025, 7:59 PM ET other material materiality 0.90 negative item 8.01 item 9.01

Terns Pharma discontinues obesity drug TERN-601 after Phase 2 miss; liver enzyme signals seen

Max placebo-adjusted weight loss 4.6% (p<0.0001) at 500 mg dose; 11.9% discontinued due to AEs.
August 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Terns Q2 net loss $24.1M; TERN-701 CML data and TERN-601 obesity data expected by year-end 2025

Net loss $24.1M for Q2 2025 vs $22.7M in Q2 2024; R&D expenses $20.4M.
May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Terns Q1 net loss $23.9M; advances TERN-701 CML and TERN-601 obesity trials

Net loss $23.9M ($0.26 EPS) vs $22.4M a year ago; R&D flat at $18.7M, G&A up to $8.7M.
March 20, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Terns Pharma reports FY2024 net loss of $88.9M; cash runway into 2028; clinical milestones for CML and obesity

FY2024 net loss $88.9M ($1.12/share), vs $90.2M in FY2023; R&D expenses $70.1M, G&A $31.8M.
February 6, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Terns Pharmaceuticals CFO Mark Vignola Departs; CEO Burroughs Takes Interim CFO Role

CFO Mark Vignola separated effective Feb 1, 2025; entered consulting agreement through July 2025.
December 3, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Terns reports positive Phase 1 CARDINAL data for TERN-701 in CML; MMR rate 50% at 3 months

15 patients enrolled across 160mg, 320mg, 400mg QD; 14 of 15 remain on treatment as of Oct 28, 2024 cutoff.
November 12, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Terns Pharma Q3 net loss $21.9M; cash $372.8M; TERN-701 data Dec 2024, TERN-601 Phase 2 start 2Q25

Net loss of $21.9M ($0.28/share) vs $29.8M loss ($0.42) in Q3 2023; R&D $15.2M, G&A $9.8M.
September 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Terns Pharmaceuticals prices upsized $150M public offering; net proceeds ~$162M

Offering of 11.9M common shares at $10.50 and 2.38M pre-funded warrants at $10.50 per underlying share.
September 9, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Terns Pharma reports positive Phase 1 data for oral GLP-1R agonist TERN-601; max placebo-adjusted weight loss 4.9%

TERN-601 achieved 4.9% placebo-adjusted mean weight loss at 740 mg QD over 28 days (p<0.0001); 5.5% absolute mean loss.